See “Trough level of infliximab is useful for assessing mucosal healing in Crohn’s disease: a prospective cohort study” on page 223.

Supplementary Fig. 1. Comparison of trough levels of infliximab (IFX) between assay A and assay B. Trough levels of IFX (TLI) were measured in the loss of response (LOR) (A) and remission (B) groups using assays A and B. Serum drawn immediately before IFX infusion was used for TLI measurements. Mean TLI values with assays A and B are 2.4±3.2 µg/mL vs. 2.3±2.7 µg/mL (P=0.33) in the LOR group (A), and 5.2±4.2 µg/mL vs. 5.2±3.8 µg/mL (P=0.85) in the remission group (B), respectively.